Precision medicine study to match drugs to cancer mutations
This article was originally published in Scrip
Executive Summary
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on 1 June launched a key component of President Barack Obama's precision medicine initiative with the start of a Phase II study aimed at matching the most appropriate targeted therapy or combinations of treatments to patients based on the molecular profile of their tumors.